Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
JPMorgan Chase voting stake in DBV Technologies slips below 10% to 9.11%

JPMorgan Chase voting stake in DBV Technologies slips below 10% to 9.11%

BitgetBitget2026/09/29 15:16
  • JPMorgan Chase disclosed crossing above the 10% threshold in DBV Technologies on Sept. 22, 2026, reaching 11.02%.
  • Holding totaled 36,654,171 shares, equal to voting rights, mainly via positions treated as assimilated ownership.
  • It then fell back below 10% on Sept. 23, 2026, cutting the stake to 9.11%.
  • Revised holding stood at 28,639,996 shares, equal to voting rights.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DBV Technologies SA published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56